Neurological disease research is evolving rapidly, with protein biomarkers playing an increasingly important role in improving our understanding of disease biology, supporting diagnosis, and informing future treatment strategies for conditions such as Alzheimer’s disease, Parkinson’s disease, and Multiple Sclerosis.

Advanced proteomics platforms have enabled significant progress in biomarker discovery, yet important challenges remain in translating these discoveries into clinical applications.

Join Betty Tijms, Head of Science at the Alzheimer Center Amsterdam, Amsterdam UMC, as she shares cutting-edge research and recent advances in cerebrospinal fluid proteomics for identifying molecular subtypes of Alzheimer’s disease.

What you will learn:

• How molecular profiling is reshaping our understanding of disease heterogeneity

• How high-throughput proteomic analysis can identify distinct biological subtypes of Alzheimer’s disease, including subtypes associated with synaptic function, immune response, vascular integrity, and metabolism

• To what extent these Alzheimer’s disease subtypes may also be detectable in blood